Bilateral Subretinal Fluid Accumulation during Erdafitinib Therapy

Abstract

Fibroblast growth factor receptor (FGFR) plays a major role in maintaining retinal pigment epithelium cells. Drugs that inhibit the FGFR pathway block the activation of the mitogen-activated protein kinase pathway, leading to the synthesis of antiapoptotic proteins and secondary subretinal fluid accumulation. Erdafitinib, a potent tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) is one such antitumour drug that has shown significant efficacy in patients with urothelial carcinoma with FGFR alterations. We present a case report demonstrating the bilateral subretinal fluid accumulation due to erdafitinib.

Keywords

• central serous chorioretinopathy
• erdafitinib
• fgfr
• mitogen-activated protein kinase
• mitogen-activated protein kinase inhibitor-associated retinopathy